UNASSIGNED: A retrospective analysis of data from patients undergoing radical surgery for CRC was performed. Only cases with results from MSI testing using immunochemistry (IHC) were analyzed. Age-based analyses were performed using two cut-off ages: 50 years. as stated in Amsterdam II guidelines, and 60 years. as outlined in the revised Bethesda criteria.
UNASSIGNED: The study population included 343 (146 female and 197 male) patients with a median age of 70 years (range 21-90 years). The prevalence of MSI-H tumors in the entire cohort was 18.7%. The prevalence of MSI-H CRC was 22.5% in the group ≤50 years vs. 18.2% in the group >50 years using the age limit in the Amsterdam II guidelines. MSI-H CRC was present in 12.6% of the group aged ≤60 years compared to 20.6% in the control group >60 years.
UNASSIGNED: MSI screening of CRC based on age alone is associated with negative selection of a relevant number of cases. MSI-H CRC is also common in elderly patients, who may be negatively selected secondary to an age-based screening algorithm. Following the results of this study, screening based on clinical criteria should be omitted in favor of systematic screening as is already internationally practiced.
■对接受CRC根治术患者的数据进行回顾性分析。仅分析具有使用免疫化学(IHC)的MSI测试结果的病例。使用两个截止年龄进行基于年龄的分析:50岁。如阿姆斯特丹II指南所述,和60年。正如修订的贝塞斯达标准中概述的那样。
■研究人群包括343名(146名女性和197名男性)患者,中位年龄为70岁(范围为21-90岁)。整个队列中MSI-H肿瘤的患病率为18.7%。在≤50岁的组中,MSI-HCRC的患病率为22.5%。使用阿姆斯特丹II指南中的年龄限制,>50岁的组中有18.2%。MSI-HCRC存在于年龄≤60岁的组的12.6%,而>60岁的对照组为20.6%。
■仅基于年龄的CRCMSI筛查与相关病例数的阴性选择相关。MSI-HCRC在老年患者中也很常见,谁可能会被否定地选择为次要的基于年龄的筛选算法。根据这项研究的结果,应省略基于临床标准的筛查,而采用国际上已经实行的系统筛查。